Nestle Uses AI to Build a New Food Business Around GLP-1 Drugs - Межа. Новини України.
Article excerpt
As appetite suppressants reshape eating habits, the food giant is studying muscle loss, hydration and nutrition needs that could define its next growth market. As informed by Reuters Nestle plans to turn the rapid spread of GLP-1 weight-loss drugs from a potential sales risk into a new business area. The company is developing products for people taking medications such as Ozempic and Wegovy, combining nutrition research with artificial intelligence capabilities. The popularity of drugs from Novo Nordisk and Eli Lilly has raised concerns among investors: appetite-suppressing medications could reduce demand for prepared foods, snacks, and beverages for an extended period. At the same time, Nestle sees a separate market in products designed to support people during rapid weight loss and help them manage its effects. Nestle’s head of technology, Stefan Palzer, said the company uses AI to analyze clinical research, identify beneficial nutrient combinations, and create products for GLP-1 consumers. We are well positioned thanks to our portfolio. This is a huge opportunity for our company. – Stefan Palzer The largest manufacturers in the GLP-1 market remain Eli Lilly, with its Mounjaro and Zepbound drugs, and Novo Nordisk, which produces Wegovy and Ozempic. According to Boston Consulting Group estimates, approximately 16 million U.S. residents take these medications, and that...
Keep reading with a free account
The rest of this article, and every signal for Nestle, is in your free account.
Extracted from this sentence
In the United States, Nestle launched Boost Advanced Nutrition Shake, which contains 35 grams of protein and is positioned as a product to support muscles during weight loss.
